Bhagiradha Chemicals Q1 FY27: A record quarter as the portfolio shifts to higher-value molecules
Bhagiradha Chemicals & Industries Ltd
BHAGCHEM
Ask Iris
Bhagiradha Chemicals Q1 FY27: A record quarter as the portfolio shifts to higher-value molecules
Bhagiradha Chemicals and Industries Limited opened FY27 with its highest ever quarterly performance, with consolidated revenue from operations of 195.0 crore in Q1 FY27, up 58% year on year. Operating profitability rose faster than revenue. EBITDA increased to 30.5 crore from 9.0 crore in Q1 FY26, and profit after tax climbed to 13.3 crore from 4.0 crore.
Margin expansion was equally notable. The quarter delivered a gross margin of 38.6%, EBITDA margin of 15.7%, and PAT margin of 6.8%. Management attributed the improvement to higher volumes, better realisations, and a favourable product mix. The narrative is consistent with the company’s stated transition, moving away from low-margin products and building a larger share of mid to high-value molecules, supported by a new facility ramp-up at its wholly owned subsidiary.
What drove Q1 FY27 performance
The company’s Q1 FY27 performance combined two levers: volumes and realisations. Volumes improved on a better demand scenario, new molecule launches, customer additions, and the ramp-up at Bheema Fine Chemicals. Realisations improved due to product mix, overall pricing improvement of the product basket, and higher sales of mid and high-value products. These factors supported both top-line growth and gross profit expansion.
From the consolidated profit and loss statement, gross profit rose to 75.2 crore from 41.5 crore in Q1 FY26. Operating leverage played out as capacity utilisation increased and fixed costs were absorbed over a larger base, resulting in a sharp EBITDA step-up. The company also reported higher depreciation and finance costs tied to the ramp-up of Bheema Fine Chemicals, but operating gains were strong enough to lift PAT sharply.
The strategic reset: portfolio, new molecules, and mix
Management described Q1 FY27 as a quarter where the company’s shift in product portfolio became more visible in the numbers. During the quarter, Bhagiradha introduced four new molecules, largely in the mid to high-value segments, and stated they contributed meaningfully to the growth trajectory. The presentation also lists the four molecules introduced in 2026: Tembotrione, Tolfenpyrad, Thifluzamide and Novaluron.
The product strategy is not only about launching more products, but also reducing dependence on a small set of molecules. The company highlighted that the top five products’ revenue contribution has steadily declined over time, from 91% in FY21 to 81% in FY26. This points to increasing breadth in the product basket, which can reduce concentration risk and make growth less reliant on a handful of actives.
At the existing Bhagiradha facility in Andhra Pradesh, management stated it is gradually reducing the share of low-margin products and redeploying capacity toward better margin products. This is positioned as a portfolio optimisation initiative, intended to improve the quality of revenues and support sustainable profitability.
Growth capex in action: Bheema Fine Chemicals ramp-up
The defining investment behind the company’s BCIL 2.0 narrative is Bheema Fine Chemicals Private Limited, a 100% subsidiary incorporated in July 2020 and which commenced commercial production on 27 March 2024. The facility is located in Karnataka and benefits from a lower stated tax rate of 17.16% for newly established manufacturing units.
The company disclosed total investments of over 850 crore under the expansion program. The Bheema plant includes 34 acres of land at Kadechur Industrial Area, installed capacity of 9,002 MT with two processing blocks, automation through Distributed Control Systems, and a Zero Liquid Discharge effluent treatment setup with water recycling. The presentation also references a solar power investment through open access mode to reduce power costs.
In Q1 FY27, management stated Bheema continued to ramp up well, with capacity utilisation nearly doubling compared with Q4 FY26. The facility is focused on mid to high-value molecules and is expected to progressively increase the contribution of high-value products.
The expansion plan is phased. Phase 1A capex of about 39 crore commenced in March 2024. Phase 1B capex of about 411 crore commenced in Q3 FY26, with ramp-up expected over 12 to 24 months from commencement. Phase 2 capex of about 400 crore is expected to commence in Q2 FY28, again with a 12 to 24 month ramp-up period.
Importantly, the company linked the investment to an operating outcome. The presentation states the expansion is expected to yield about 1.5x asset turn at full potential with improved margin. While it does not provide a time-bound RoCE target, it does suggest management is thinking about asset productivity beyond capacity creation.
Backward integration and operations: building an entry barrier
Backward integration is positioned as a structural advantage in the presentation, both for margin resilience and for reducing reliance on imported inputs. The deck illustrates multi-stage backward integration and states that future backward integration planned to N-7 with 13 process stages is expected to increase margins. It further states backward integration is planned to increase to N-9 level with 16 process stages by FY27.
Alongside integration, management emphasised process upgrades, adoption of new technologies, and debottlenecking to improve throughput and utilisation. These initiatives are expected to enhance operating efficiency and contribute to margin expansion. The company also highlighted infrastructure around ESG and compliance, including Zero Liquid Discharge effluent treatment, online continuous monitoring systems, and audits by external agencies such as NEERI, DNV, and others.
The investor lens: what to track after the record quarter
Q1 FY27 shows strong operating leverage when utilisation and mix improve, but the presentation also flags areas investors typically monitor in a capex-led expansion cycle.
First, the company’s historical ratios reflect the impact of the investment phase. In FY26, RoCE was 4% and asset turnover was 0.8, with the deck attributing this to capex done for the Bheema plant over the last two years. Second, working capital intensity increased in FY26. Inventory days were 170 and debtor days were 144, while creditor days were 122. Even if this partly reflects ramp-up and stocking, it indicates cash can remain tied up as the new facility scales.
Third, management noted that while raw material prices were broadly stable, select crude-linked inputs saw increases due to geopolitical developments in West Asia. This is relevant because the margin improvement in Q1 FY27 was supported by stable raw materials, process improvements, and mix. If input volatility rises, the sustainability of margin gains will depend on pricing power, integration depth, and operational execution.
Finally, the company’s own growth ambition is explicit. The presentation states a consolidated revenue target of about 3.5x over the next 3 to 5 years, driven by operating efficiency and a better margin profile. The path to that outcome depends on continued ramp-up at Bheema, steady molecule launches in mid to high-value segments, and execution on backward integration.
Closing thought
Bhagiradha Chemicals’ Q1 FY27 results are a clear step change in quarterly performance, supported by higher volumes, better realisations, and a richer product mix. The ramp-up of Bheema Fine Chemicals and the stated shift away from low-margin products are central to the company’s strategy. The next few quarters will likely be judged on two measurable themes already visible in the presentation: sustained utilisation improvement at Bheema and the ability to maintain improved margins while managing working capital and input-cost volatility.
Frequently Asked Questions
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker